IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1–9. (Cancelled)

10. (Currently amended) A pharmaceutical composition comprising (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable carrier or adjuvant, wherein the prodrug is of the ~~general~~ formula



or a salt thereof;

wherein R^1 is selected from the group consisting of acyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, acetal, ketal, $-C(O)NR^2R^3$, $-C(O)NHR^2$, $-P(O_2H)OR^2$ and $-P(O_2H)R^2$, wherein R^2 and R^3 are independently selected from H, C_{1-6} alkyl, C_{3-10} cycloalkyl, benzyl and phenyl~~, or a salt thereof; and~~

wherein the at least one pharmaceutically acceptable carrier or adjuvant is selected from the group consisting of fillers, disintegrants, binders, lubricants, stabilizers, flavors, antioxidants, preservatives, dispersants, buffers and electrolytes.

11. (Previously presented) The composition of Claim 10, comprising (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt thereof.

12. (Previously presented) The composition of Claim 10, comprising a prodrug or a salt thereof wherein R^1 is selected from C_{1-6} alkylcarbonyl, C_{3-10} cycloalkylcarbonyl, benzoyl, $-C(O)NR^2R^3$ and $-C(O)NHR^2$.

13. (Previously presented) The composition of Claim 10, that is adapted for transdermal, transmucosal or parenteral administration.

14. (Previously presented) The composition of Claim 10, wherein the (S)-2-N-propylamino-5-hydroxytetralin or salt or prodrug thereof is present as a pure (S)-enantiomer.

15. (Withdrawn) A method for treatment or prophylaxis of a disease or for ablactation in a subject, comprising administering to the subject (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is of the general formula



wherein R^1 is selected from the group consisting of acyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, acetal, ketal, $-C(O)NR^2R^3$, $-C(O)NHR^2$, $-P(O_2H)OR^2$ and $-P(O_2H)R^2$, wherein R^2 and R^3 are independently selected from H, C_{1-6} alkyl, C_{3-10} cycloalkyl, benzyl and phenyl, or a salt thereof; and

wherein the disease is selected from the group consisting of depressions, anxiety disorders, sexual dysfunctions, galactorrhea, acromegaly, glaucoma, cognitive disorders, restless leg syndrome, attention deficit hyperactivity syndrome (ADHS), hyperprolactinemia, hyperprolactinoma, eating disorders, dopa-sensitive dyskinesias, Parkinson-associated movement disorders, dopa- and neuroleptic-induced movement disorders, cocaine, alcohol, opiate and nicotine addictions, and neurodegenerative disorders.

16. (Withdrawn) The method of Claim 15, wherein the disease is selected from the group consisting of restless leg syndrome, L-dopa-sensitive dyskinesias, Parkinson-associated movement disorders, L-dopa- and neuroleptic-induced movement disorders, and cocaine, alcohol, opiate and nicotine addictions.

17. (Withdrawn) The method of Claim 15, wherein the disease is a movement disorder

which is

(a) morbus Parkinson associated,

(b) induced by L-dopa, or

(c) induced by a neuroleptic.

18. (Withdrawn) A method for treating a disease that responds to therapy by dopamine or dopamine agonists, comprising administering to a subject having the disease (S)-2-N-propylamino-5-hydroxytetralin or a pharmaceutically acceptable salt or prodrug thereof, wherein the prodrug is of the general formula



wherein R^1 is selected from the group consisting of acyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, acetal, ketal, $-C(O)NR^2R^3$, $-C(O)NHR^2$, $-P(O_2H)OR^2$ and $-P(O_2H)R^2$, wherein R^2 and R^3 are independently selected from H, C_{1-6} alkyl, C_{3-10} cycloalkyl, benzyl and phenyl, or a salt thereof.

19. (Currently amended) A compound having the ~~general~~ formula



or a salt thereof;

wherein R^1 is selected from the group consisting of acyl, alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl, acetal, ketal, $-C(O)NR^2R^3$, $-C(O)NHR^2$, $-P(O_2H)OR^2$ and $-P(O_2H)R^2$, wherein R^2 and R^3 are independently selected from H, C_{1-6} alkyl, C_{3-10} cycloalkyl, benzyl and phenyl~~, or a salt thereof~~;

said compound being in the (S)-configuration.

20. (Previously presented) The compound of Claim 19, wherein R^1 is selected from C_{1-6} alkylcarbonyl, C_{3-10} cycloalkylcarbonyl, benzoyl, $-C(O)NR^2R^3$ and $-C(O)NHR^2$.

21. (Previously presented) The compound of Claim 19 that, when administered to a human body, is cleaved, processed or metabolized to (S)-2-N-propylamino-5-hydroxytetralin.